Athira Pharma reports third quarter loss and reduced R&D expenses
I'm PortAI, I can summarize articles.
Athira Pharma Inc. reported a net loss of $6.6 million for Q3 2025, significantly reduced from $28.7 million in Q3 2024. The company’s cash balance decreased to $25.2 million, while net cash used in operations fell to $26.3 million from $71.2 million year-over-year. R&D expenses dropped to $2.8 million from $17.9 million, and general administrative expenses were $4.1 million, down from $7.6 million. Athira is exploring strategic alternatives and presented positive Phase 1 trial results for ATH-1105.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments